Mario Perro

8PUBLICATIONS

50CO-AUTHORS

Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)BiomaterialsMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jun 12, 2026

Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor control.

|Sep 11, 2024

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret

|Mar 06, 2024

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.

C Grandclément, C Estoppey, E Dheilly

|May 16, 2023

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.

Blandine Pouleau, Carole Estoppey, Perrine Suere

|Mar 27, 2021

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.

Eva Sum, Moritz Rapp, Philipp Fröbel

|Jan 06, 2021

Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.

Floriana Cremasco, Elena Menietti, Dario Speziale

Pageof 2

Frequent Collaborators

Thierry Monney

Thomas Matthes

Claire M Edwards

James R Edwards

Catherine Pellat-Deceunynck

Michael R Dyson

Stefano Sammicheli

Christian Klein

Eva Sum

Pablo Umana

Frequent Collaborators

Thierry Monney

Thomas Matthes

Claire M Edwards

James R Edwards